NCT07297797Active, not recruitingPhase 2
Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-9563 in Patients With Mild to Moderate Hypertension
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 238 (actual)
- First submitted
- 9 Dec 2025
- Start date
- 14 Jan 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Diseases
- High blood pressure
- NCT number
- NCT07297797
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 238
- From 14 Jan 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening;
- Presence of uncontrolled severe arrhythmia within 6 months prior to screening;
- Suspected allergy to the investigational drug or any of its components;
- Use of any medication affecting blood pressure within 4 weeks prior to screening, or planned use during the study period;
Other illness
- Secondary hypertension;
- Type 1 diabetes or poorly controlled type 2 diabetes;
- Other diseases requiring Renin-Angiotensin-Aldosterone System (RAAS) inhibitor therapy, besides hypertension;
Other
- Orthostatic hypotension;
- Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;
Who the study is looking for
- The subject voluntarily signs the informed consent form.
- Male or female, aged ≥ 18 years and ≤ 75 years;
- Patients with mild to moderate hypertension;
- At the Screening and Baseline periods, the mean sitting office systolic blood pressure is \> 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and \< 160 mmHg.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Anzhen Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.